Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma

Mapatumumab and lexatumumab (targeting death receptor 4 (DR4) and 5 (DR5), respectively) are agonistic TRAIL receptor antibodies that induce apoptosis in a wide range of cancer cells. The potency of mapatumumab and lexatumumab was assessed in mono therapy protocols, and the ability to sensitize for...

Descripción completa

Detalles Bibliográficos
Autores principales: Engesæter, Birgit, Engebraaten, Olav, Flørenes, Vivi Ann, Mælandsmo, Gunhild Mari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447808/
https://www.ncbi.nlm.nih.gov/pubmed/23029050
http://dx.doi.org/10.1371/journal.pone.0045492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447808/
https://www.ncbi.nlm.nih.gov/pubmed/23029050
http://dx.doi.org/10.1371/journal.pone.0045492

Ejemplares similares